D.E. Shaw & Co
VBIV

D.E. Shaw & Co’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

D.E. Shaw & Co’s Portfolio VBIV Stock Details VBIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-731
Closed -$8.58K – 4980
2022
Q4 		$8.58K Sell
731
-900
-55% -$15.9K ﹤0.01% 4624
2022
Q3 		$35K Buy
+1,631
New +$44K ﹤0.01% 4735
2020
Q1 		– Sell
-723
Closed -$30K – 4340
2019
Q4 		$30K Sell
723
-1,442
-67% -$31.6K ﹤0.01% 3911
2019
Q3 		$31K Buy
+2,165
New +$45.3K ﹤0.01% 3745

Other funds holding VBIV

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

D.E. Shaw & Co's VBIV Position: Q1 2023 in Review

D.E. Shaw & Co sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q1 2023, closing a stake of 731 shares — an estimated $8.58K sold.

D.E. Shaw & Co first reported a position in VBIV in Q3 2019 and held it in 4 quarters. The position peaked at $35K in Q3 2022. 95 funds tracked by Wall St. Rank hold VBIV as of Q1 2023.

  • D.E. Shaw & Co reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q1 2023 after selling out during the quarter.
  • D.E. Shaw & Co sold 731 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q1 2023, an estimated $8.58K.
  • D.E. Shaw & Co first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q3 2019 and held it in 4 quarters.
  • D.E. Shaw & Co's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $35K in Q3 2022.
  • 95 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q1 2023.

Based on D.E. Shaw & Co's 13F filing for Q1 2023, filed 15 May 2023.